For Sun Pharma, its investment in speciality business is paying off, as it is becoming a driver of growth for the company’s US business. Cipla’s ‘One India’ strategy, focusing on branded prescription, trade generics and consumer health brands, is leading to continued core portfolio momentum across businesses.
BFSI remains a key driver of market resilience despite global jitters: Pankaj Pandey
Overall, sense is that the domestic flows in core categories are intact from a mutual fund perspective and also, from the FII perspective, a bigger
May 15, 2025